Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended																12 Months Ended
	Jun. 27, 2015		Mar. 28, 2015		Dec. 27, 2014		Sep. 27, 2014		Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Numerator:
Net income	$ 56.4	[1]	$ (94.9)	[2]	$ 70.2	[3]	$ 96.3	[4]	$ 131.7	[5]	$ 48.1	[6]	$ (86.0)	[7]	$ 111.4	[8]	$ 128.0	$ 205.3	$ 441.9
Denominator:
Weighted average shares outstanding for basic EPS	146.3		140.8		136.3		133.9		133.8		133.7		98.7		94.2		139.3	115.1	93.9
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements																	0.5	0.5	0.6
Weighted average shares outstanding for diluted EPS	146.8		140.8		136.8		134.4		134.3		134.3		98.7		94.7		139.8	115.6	94.5
Antidilutive share-based awards oustanding																	0.1	0.1	0.2
Payments of Dividends																	$ 64.8	$ 46.1	$ 33.0
Common Stock, Dividends, Per Share, Declared																	$ 0.4600	$ 0.3900	$ 0.3500

[1] Includes legal and consulting fees related to our defense against Mylan N.V. of $13.4 million, acquisition costs of $18.5 million, goodwill impairment of $6.8 million, losses on derivatives terminated with extinguishment of associated debt and associated with hedging the pending GSK acquisition of $5.5 million, losses on equity method investments of $3.5 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and an initial payment made in connection with an R&D agreement of $18.0 million.

[2] Includes acquisition costs totaling $2.0 million, an increase in litigation accrual of $2.0 million, restructuring charges of $1.1 million, Omega financing fees of $18.6 million, and losses on derivatives associated with the Omega acquisition of $258.2 million.

[3] Includes restructuring charges of $2.4 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, Omega transaction expenses of $17.8 million, losses on derivatives associated with the Omega acquisition of $64.7 million, equity method investment losses of $3.0 million, income from transfer of rights agreement of $12.5 million, and $9.6 million loss on extinguishment of debt.

[4] Includes acquisition costs of $1.1 million, restructuring charges of $1.7 million, equity method investment losses of $3.1 million, and a $1.2 million investment distribution.

[5] Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.

[6] Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.

[7] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D totaling $6.0 million related to Paddock and Rosemont.

[8] Includes Elan transactions costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.